Anemia in Elderly Market Report 2025

This Anemia in Elderly market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The anemia in elderly market size has grown strongly in recent years. It will grow from $2.75 billion in 2024 to $3.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historical period can be attributed to factors such as nutritional deficiencies, chronic diseases, inflammation, bone marrow disorders, and blood loss.

The anemia in elderly market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%.The anticipated growth in the forecast period is driven by an aging population, a rising prevalence of chronic diseases, advancements in diagnostic tools, increased healthcare awareness, and better access to treatment. Key trends during this period include AI-driven diagnostics, wearable health monitors, advanced blood analysis tools, telehealth integration, and personalized medicine solutions.

The growing elderly population is expected to drive the growth of the anemia in the elderly market. As the global population ages, with increased life expectancy, declining birth rates, and the aging of large cohorts, the proportion of individuals aged 65 and older is steadily increasing. This demographic shift leads to a higher prevalence of age-related and chronic conditions, which are significant causes of anemia in older adults. The rise in cases of anemia among the elderly, due to factors such as nutritional deficiencies, chronic diseases, and the effects of aging, is fueling the demand for diagnosis, management, and treatment of the condition. For example, in July 2024, the Office for National Statistics (ONS) reported that the number of people aged 65 and older in the UK grew to 12.7 million in 2022 from 11 million in 2021. This growth in the elderly population is driving the expansion of the anemia in the elderly market.

Leading companies in the elderly anemia market are concentrating on technological innovations, particularly personalized treatments, to optimize the treatment process, enhance patient results, minimize side effects, and improve overall healthcare efficiency. Personalized treatments are tailored to the unique needs of each patient. For example, in March 2024, Cadila Pharmaceuticals, based in India, unveiled Redshot FCM, a new iron injection aimed at treating iron deficiency anemia in patients who cannot tolerate oral iron. This intravenous formulation provides sufficient iron and maintains a high safety standard. Redshot FCM utilizes an advanced Ferric Carboxymaltose formula to enhance iron delivery and absorption. This development highlights a commitment to advancing healthcare by creating therapies tailored to individual patient needs, ultimately leading to improved outcomes for those with iron deficiency anemia.

In August 2022, CSL Limited, an Australian biotechnology company, acquired Vifor Pharma AG, a Swiss pharmaceutical company specializing in treatments for iron deficiency, especially among elderly patients and those with chronic kidney disease (CKD). This acquisition strengthens CSL's leadership in the iron deficiency anemia market and expands its presence in addressing the needs of various patient populations, further propelling the growth of treatments for anemia in the elderly.

Major players in the anemia in elderly market are Johnson & Johnson, Roche Holding AG, Merck & Co Inc, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Japan Tobacco Inc, Fresenius Medical Care AG, Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, CSL Limted, Daiichi Sankyo Company Limited, Amag Pharmaceuticals, Akebia Therapeutics Inc, Pharmacosmos A/S, Rockwell Medical Inc, Bioage Labs Inc, Shield Therapeutics Plc, MegaPro Biomedical Co Ltd.

North America was the largest region in the anemia in elderly market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anemia in elderly report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anemia in elderly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anemia in the elderly refers to a condition where the number of red blood cells (RBCs) or hemoglobin levels falls below the normal range, reducing the blood's ability to carry oxygen in older adults (typically those aged 65 and older). This condition is often caused by nutritional deficiencies, chronic illnesses, or age-related physiological changes.

The main products used to treat anemia in the elderly include tablets and injectables. Tablets are solid oral medications commonly prescribed for older adults with anemia. Treatment options include iron supplements, erythropoietin or erythrocyte-stimulating agents, vitamin B12 supplements, and folic acid supplements. These treatments can be administered orally or parenterally and are typically provided through hospital pharmacies, online pharmacies, and retail pharmacies.

The anemia in elderly market research report is one of a series of new reports that provides anemia in elderly market statistics, including anemia in elderly industry global market size, regional shares, competitors with a anemia in elderly market share, detailed anemia in elderly market segments, market trends and opportunities, and any further data you may need to thrive in the anemia in elderly industry. This anemia in elderly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anemia in elderly market consists of revenues earned by entities by providing services such as diagnostic testing, medical consultations and treatment plans, and administration of iron infusions or blood transfusions. The market value includes the value of related goods sold by the service provider or included within the service offering. The anemia in elderly market also includes sales of iron supplements, vitamin B12, folic acid supplements, and diagnostic equipment such as hemoglobin meters and blood test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.